zovegalisib
RLY-2608 Small Molecule Target: PI3Kα
Relay Therapeutics
Most recent annual filing: 2026-02-26
- Zovegalisib 1L combo filingBy YE2026Zovegalisib 1L combo filing, By YE2026, material
- Zovegalisib ReInspire readoutBy YE2026Zovegalisib ReInspire readout, By YE2026, material
- Zovegalisib ReDiscover-2 enrollment doneBy YE2026Zovegalisib ReDiscover-2 enrollment done, By YE2026, notable
- Zovegalisib + atirmociclib triplet 1L-supportive1H 2027Zovegalisib + atirmociclib triplet 1L-supportive, 1H 2027, notable
- Zovegalisib + atirmociclib AI Ph3Early 2027Zovegalisib + atirmociclib AI Ph3, Early 2027, routine
- DESRES exclusivity window corporate updateAug 2027DESRES exclusivity window corporate update, Aug 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
Technology platforms
Dynamo
Motion-Based Drug Design platform integrating experimental and computational approaches (cryo-EM, molecular dynamics, machine learning) to gain insights into protein conformational dynamics; focused on precision oncology and genetic diseases, targeting intractable or inadequately addressed protein targets
Discontinued (1)
- migoprotafib — undisclosed · Genentech terminated the Genentech Agreement without cause; we will not continue development of migoprotafib
Biotech Distilled coverage (1)
- 2026-08-10 Relay Therapeutics (RLAY) — Scientific Deep Dive for Zovegalisib and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.